City of Hope | Strategic Alliance Partners

February 05, 2021

Introduced today in the state Senate, legislation details six rights for every cancer patient in California.

January 20, 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

January 10, 2021

In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.

December 23, 2020

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

December 01, 2020

The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.

October 07, 2020

City of Hope is investigating an innovative treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis that is inexpensive and has few serious side effects, in a new clinical trial.

October 01, 2020

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

September 22, 2020

The comprehensive cancer center has also dosed its first patient in chlorotoxin CAR T cell therapy trial.

September 15, 2020

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

September 10, 2020

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

August 28, 2020

Jeffery Weitzel, MD, discusses the identification of ​Li-Fraumeni syndrome.

August 28, 2020

Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular carcinoma.

August 27, 2020

Charles Brenner, PhD, joins City of Hope as chair of first department focused on diabetes and cancer metabolism.

June 24, 2020

Preeminent health care innovator and leader Glenn D. Steele Jr, MD, PhD, has been elected the new board chair of City of Hope effective June 1.

June 09, 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

June 09, 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

April 23, 2020

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

April 23, 2020

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

April 09, 2020

Vincent Chung, MD, discusses the importance of genomic testing in pancreatic cancer.

April 08, 2020

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.